0001209191-17-047901.txt : 20170807
0001209191-17-047901.hdr.sgml : 20170807
20170807164205
ACCESSION NUMBER: 0001209191-17-047901
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170803
FILED AS OF DATE: 20170807
DATE AS OF CHANGE: 20170807
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mahatme Sandesh
CENTRAL INDEX KEY: 0001511034
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14895
FILM NUMBER: 171012067
MAIL ADDRESS:
STREET 1: C/O CELGENE CORPORATION
STREET 2: 86 MORRIS AVENUE
CITY: SUMMIT
STATE: NJ
ZIP: 07901
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc.
CENTRAL INDEX KEY: 0000873303
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 930797222
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-274-4000
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Sarepta Therapuetics, Inc.
DATE OF NAME CHANGE: 20120712
FORMER COMPANY:
FORMER CONFORMED NAME: AVI BIOPHARMA INC
DATE OF NAME CHANGE: 19980930
FORMER COMPANY:
FORMER CONFORMED NAME: ANTIVIRALS INC
DATE OF NAME CHANGE: 19970123
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-08-03
0
0000873303
Sarepta Therapeutics, Inc.
SRPT
0001511034
Mahatme Sandesh
215 FIRST STREET, SUITE 415
CAMBRIDGE
MA
02142
0
1
0
0
EVP, CFO & CBO
Common Stock
2017-08-03
4
M
0
13298
A
47159
D
Common Stock
2017-08-03
4
F
0
6264
37.88
D
40895
D
Restricted Stock Units
2017-08-03
4
M
0
13298
0.00
D
Common Stock
13298
0
D
Restricted stock units convert into common stock on a one-for-one basis.
Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of restricted stock units granted on March 3, 2017.
On March 3, 2017, the reporting person was granted restricted stock units that vest based on the Company's satisfaction of certain performance criteria. The first performance criterion was met on August 3, 2017, resulting in vesting of 50% of such restricted stock units.
/s/David Tyronne Howton, as Attorney-in-Fact for Sandesh Mahatme
2017-08-07